With no prior business experience, he started his journey with just two employees and transformed his company into a global ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

Sun Pharmaceuticals, India's largest drugmaker by revenue, reported second-quarter profit above analysts' estimates on Monday ...

Shares of Sun Pharmaceutical Industries declined five per cent to Rs 1,766.15 in early trade on the BSE on Monday following a ...

Sun Pharmaceutical Industries Ltd. 524715 shares slid 1.14% to 1,779.30 Indian rupees Wednesday, on what proved to be an all-around poor trading session for the stock market, with the BSE SENSEX Index ...

How will India’s leading drugmaker handle legal setbacks, volatile market trends, and competition in generics and specialty products?

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Given the investments of around $576 million and the peak revenues potential upwards of $200 million, four years down the ...

Thirty out of the 41 analysts tracking the company have a 'buy' rating on the stock, seven suggest a 'hold' and four have a ...

This decision delays Sun Pharma's planned US launch of the product, which could be deferred for several months if the company ...

Net profit of drugmaker Sun Pharmaceutical Industries rose 28% year-on-year to ₹3,040 crore for the quarter ended Sepember ...

Today, 173 companies will disclose their Q2 earnings, including Airtel, Sun Pharma, and Adani Power. Bharti Airtel is ...